22 Apr FSHD NEWS: Apabetalone May Repress Toxic Gene in Rare Muscular Dystrophy (FSHD)
Apabetalone (RVX-208) may become a promising therapy to treat facioscapulohumeral muscular dystrophy (FSHD), according to results announced by the pharmaceutical company Resverlogix. Researchers found this drug acts by switching off the DUX4 gene, which is abnormally active in the muscles of FSHD patients, causing inflammation and...